Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt

Cocaine Dependence: early-phase trial registry

3 of 40 indexed Cocaine Dependence trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #368 of 28,707 conditions by registered trial count.

40 US clinical trials · 3 currently recruiting · #368 of 28,707 conditions by registered trial count

Cocaine Dependence: 40 US clinical trials tracked, 3 recruiting.

Cocaine Dependence is the subject of 40 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Yale University, running 6 of these trials.

Enrollment posture brief

Registry condition cocaine-dependence

OPEN 3 | RECR 8% | LATE 0 | EARLY 27 | RANK #368 | SPON 6

Nearest open-share peer: Sinusitis (8% recruiting · 13 trials)

Anatomic Stage IIIA Breast C35%Human Papilloma Virus35%Human Immunodeficiency Virus30%Heart Failure, Congestive12.5%Cocaine Dependence (this)8%
Open-enrollment share among volume-matched conditions near Cocaine Dependence

Cocaine Dependence lists 3 open slots (8% of 40 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cocaine Dependence on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cocaine Dependence is recruiting below its size-band peers.

    3 of 40 indexed trials (7.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Cocaine Dependence research.

    Yale University accounts for 6 of 40 trials (15%). 24 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cocaine Dependence enrolment sits around 106 participants.

    Median target enrolment is 106 among the 39 trials that report a genuine target (sentinel values excluded). 19 of those (48.7%) plan for fewer than 100 participants.

  4. Cocaine Dependence research is mostly interventional.

    37 interventional and 3 observational studies make up this index (92.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 110Phase 217

Open and recent trials

40 total, page 1 of 1

RECRUITING 7,500 participants

Substance Abuse Pre-Treatment Screening Study

The University of Texas Health Science Center, Houston

NCT00439049

RECRUITING Phase 1 150 participants

Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals

Weill Medical College of Cornell University

NCT02455479

RECRUITING NA 120 participants

Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder

Icahn School of Medicine at Mount Sinai

NCT07318480

ACTIVE NOT RECRUITING Phase 2 65 participants

Clavulanic Acid for the Treatment of Cocaine Use Disorder

Temple University

NCT05562349

COMPLETED NA 332 participants

Effectiveness of Extended Treatments for Drug Dependence

University of Pennsylvania

NCT00685659

COMPLETED Phase 2 250 participants

Clinical Trial of Topiramate for Cocaine Addiction

Johns Hopkins University

NCT00685178

COMPLETED NA 240 participants

Vouchers vs. Prizes for Cocaine-Dependent Methadone Patients - 2

UConn Health

NCT00249535

COMPLETED Phase 2 207 participants

Vigabatrin for the Treatment of Cocaine Dependency

Catalyst Pharmaceuticals

NCT01281202

COMPLETED Phase 2 186 participants

Vigabatrin for Treatment of Cocaine Dependence

Catalyst Pharmaceuticals

NCT00611130

COMPLETED Phase 2 170 participants

Topiramate for Alcohol and Cocaine Dependence

Kyle Kampman

NCT00167245

COMPLETED Phase 2 169 participants

Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence

New York State Psychiatric Institute

NCT01811940

COMPLETED Phase 1 166 participants

Long Term Maintenance of Drug Abstinence

Treatment Research Institute

NCT00842517

COMPLETED Phase 1 152 participants

Valproate Efficacy in Cocaine-Bipolar Comorbidity

University of Miami

NCT00240110

COMPLETED Phase 2 150 participants

Effectiveness of Enhanced Treatments for Drug Dependence

University of Pennsylvania

NCT01153477

COMPLETED Phase 2 145 participants

Behavioral Treatment for Cocaine Dependent Women

Yale University

NCT00914381

COMPLETED Phase 2 139 participants

Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence

New York State Psychiatric Institute

NCT00553319

COMPLETED 120 participants

Risk Perception in Drug-Dependent Adults With and Without Schizophrenia

National Institute on Drug Abuse (NIDA)

NCT01031563

COMPLETED Phase 2 118 participants

Disulfiram for Cocaine Abuse

University of Arkansas

NCT00395850

COMPLETED Phase 2 115 participants

Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1

New York State Psychiatric Institute

NCT00061087

COMPLETED Phase 2 108 participants

Citalopram for Cocaine Dependence

Joy Schmitz

NCT01535573

COMPLETED NA 106 participants

Cocaine Withdrawal and Pharmacotherapy Response

Yale University

NCT00566969

COMPLETED Phase 2 87 participants

Combined Treatment for Cocaine-Alcohol Dependence - 1

The University of Texas Health Science Center, Houston

NCT00218569

COMPLETED Phase 1 72 participants

Rivastigmine and Huperzine A as Treatments for Cocaine Dependence

Baylor College of Medicine

NCT01030692

COMPLETED Phase 1 60 participants

Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues

Yale University

NCT00585520

COMPLETED Phase 1 45 participants

Complementary Combination Therapy for Cocaine Dependence

Baylor College of Medicine

NCT02538744

COMPLETED NA 45 participants

A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction

Embera NeuroTherapeutics

NCT00567814

COMPLETED NA 44 participants

Modafinil, Sleep, and Cognition in Cocaine Dependence

Yale University

NCT00582491

COMPLETED NA 41 participants

Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET

Yale University

NCT03527485

COMPLETED NA 35 participants

Neurobehavioral Measurement of Substance Users in Outpatient Treatment Setting

Hunter Holmes Mcguire Veteran Affairs Medical Center

NCT03662529

COMPLETED Phase 2 32 participants

Carvedilol for Psychostimulant Dependence

University of Arkansas

NCT01171183

COMPLETED Phase 2 30 participants

PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)

Tong Lee

NCT01377662

COMPLETED NA 29 participants

Ovarian Hormones and Stress Induced Drug Craving

Medical University of South Carolina

NCT02098434

COMPLETED Phase 2 24 participants

Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects

Boston University

NCT00322309

COMPLETED NA 24 participants

Exercise as a Behavioral Treatment for Cocaine Dependence

Baylor College of Medicine

NCT01601743

COMPLETED Phase 1 23 participants

Caffeine and Cocaine

Virginia Commonwealth University

NCT00733993

COMPLETED Phase 1 17 participants

Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence

New York State Psychiatric Institute

NCT01486810

COMPLETED Early Phase 1 15 participants

n-Acetylcysteine and Cocaine

University of Kentucky

NCT02141620

COMPLETED Phase 2 8 participants

Glutamatergic Modulation of Cocaine-related Deficits

New York State Psychiatric Institute

NCT01790490

COMPLETED Phase 1 6 participants

Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS

Yale University

NCT02124941

COMPLETED

Gender Differences in Response to Cues in Cocaine Dependence

Medical University of South Carolina

NCT00969943

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 17

Named interventions

Most-linked intervention names on Cocaine Dependence records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
13 trials
Placebo Other
3 trials
Topiramate Drug
2 trials
Naltrexone Drug
2 trials
Modafinil Drug
2 trials
placebo Drug
2 trials
Telephone Monitoring and Counseling - Enhanced Behavioral
1 trials
medication management Behavioral
1 trials

US sites by state

Facility locations filed on Cocaine Dependence trials. A trial with sites in several states counts in each.

Texas 9 trials
New York 8 trials
Pennsylvania 7 trials
Connecticut 7 trials
South Carolina 4 trials
Maryland 4 trials
Massachusetts 3 trials
Florida 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cocaine Dependence page

40 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Cocaine Dependence trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Yale University sponsors the most Cocaine Dependence trials on record, review their full trial history before evaluating a specific study. See Yale University's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cocaine Dependence condition card totals 40 registered trials; most-linked intervention Placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.